Who Exports Velpatasvir from India — 103 Suppliers Behind a $24.7M Market
India's velpatasvir export market is supplied by 103 active exporters who collectively shipped $24.7M across 671 shipments. MYLAN LABORATORIES LIMITED leads with a 49.6% market share, followed by HETERO LABS LIMITED and EURO LIFECARE PRIVATE LIMITED. The top 5 suppliers together control 92.8% of total export value, reflecting a concentrated market structure.
Top Velpatasvir Exporters from India — Ranked by Export Value
MYLAN LABORATORIES LIMITED is the leading velpatasvir exporter from India, holding a 49.6% share of the $24.7M market across 671 shipments from 103 exporters. The top 5 suppliers — MYLAN LABORATORIES LIMITED, HETERO LABS LIMITED, EURO LIFECARE PRIVATE LIMITED, NATCO PHARMA LIMITED, KARDI TRADING PRIVATE LIMITED — collectively control 92.8% of total export value, indicating a highly concentrated market. Individual shares are: MYLAN LABORATORIES LIMITED (49.6%), HETERO LABS LIMITED (21.0%), EURO LIFECARE PRIVATE LIMITED (15.7%), NATCO PHARMA LIMITED (5.2%), KARDI TRADING PRIVATE LIMITED (1.3%).
Top Velpatasvir Exporters from India
Ranked by export value · 103 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | MYLAN LABORATORIES LIMITED SOFOSBUVIR 400MG + VELPATASVIR 100MG TABMYVELPA -- SOFOSBUVIR 400MG-VELPATASVIRSOFOSBUVIR 400 MG + VELPATASVIR 100 MG TAB 28S | $12.2M | 23 | 49.6% |
| 2 | HETERO LABS LIMITED HEPVEL SOFOSBUVIR 400 MG + VELPATASVIR 1SOFOSBUVIR 400MG/VELPATASVIR100 MG TABLEHEPVEL SOFOSBUVIR 400 MG+VELPATASVIR 100 | $5.2M | 17 | 21.0% |
| 3 | EURO LIFECARE PRIVATE LIMITED SOFOSBUVIR 400MG + VELPATASVIR 100MG TABVELPANATSOFOSBUVIR 400MG + VELPATASVIR 100MG TABLETS - MYHEP ALL | $3.9M | 2 | 15.7% |
| 4 | NATCO PHARMA LIMITED MYVELPA -- SOFOSBUVIR 400MG-VELPATASVIRMYVELPA - SOFOSBUVIR 400MG - VELPATASVIRVELPATASVIR SOLID DISPERSION 50% W/WCI NO:524301) | $1.3M | 5 | 5.2% |
| 5 | KARDI TRADING PRIVATE LIMITED SOFOSBUVIR 400MG + VELPATASVIR 100 MG (SSOFOSBUVIR 400MG VELPATASVIR 100MG SOVIRHEPVEL SOFOSBUVIR+VELPATASVIR TABLET 2448 CON | $311.7K | 3 | 1.3% |
| 6 | HEET HEALTHCARE PRIVATE LIMITED SOFOSBUVIR 400MG + VELPATASVIR 100MG TABVELSOF SOFOSBUVIR 400 MG + VELPATASVIR 1SOFOSBUVIR 400MG + VELPATASVIR 100MG TABLETS - MYHEP ALL | $262.0K | 12 | 1.1% |
| 7 | ASPIDA LIFE SCIENCES PRIVATE LIMITED MYVELPA -- SOFOSBUVIR 400MG-VELPATASVIRMYVELPA - SOFOSBUVIR 400MG - VELPATASVIRVELPATASVIR SOLID DISPERSION 50% W/WCI NO:524301) | $146.1K | 3 | 0.6% |
| 8 | LEOWIN HEALTHCARE LLP SOFOSBUVIR 400MG + VELPATASVIR 100MG TABSOFOSBUVIR 400MG + VELPATASVIR 100MG TABLETS - MYHEP ALL | $107.7K | 3 | 0.4% |
| 9 | PROSPERA LIFE SCIENCES PRIVATE LIMITED SOFOSBUVIR 400MG + VELPATASVIR 100 MG (SSOFOSBUVIR 400MG VELPATASVIR 100MG SOVIRHEPVEL SOFOSBUVIR+VELPATASVIR TABLET 2448 CON | $88.8K | 4 | 0.4% |
| 10 | SACRED LEAVES PRIVATE LIMITED SOFOSBUVIR 400MG + VELPATASVIR 100MG TABVELSOF SOFOSBUVIR+VELPATASVIR TABLETSOFOSBUVIR 400MG + VELPATASVIR 100MG TABLETS - MYHEP ALL | $76.7K | 3 | 0.3% |
| 11 | GALAXY SUPER SPECIALITY | $76.4K | 6 | 0.3% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Velpatasvir exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| MYLAN LABORATORIES LIMITED | Approved | Yes, as of April 202 | Yes | Not verified | FDA-approved; WHO-GMP certified in April 2025; EU-GMP compliant. |
| HETERO LABS LIMITED | Approved | Yes, as of September | Yes | Not verified | FDA-approved; WHO-GMP certified in September 2025; EU-GMP compliant. |
| NATCO PHARMA LIMITED | Approved | Yes, as of November | Yes | Not verified | FDA-approved; WHO-GMP certified in November 2025; EU-GMP compliant. |
TransData Nexus reviewed the regulatory standing of 3 leading Velpatasvir exporters from India. 3 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 3 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Velpatasvir sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for the production of active pharmaceutical ingredients (APIs). The city hosts numerous manufacturers specializing in APIs, contributing significantly to India's pharmaceutical exports. Companies like Manus Aktteva Biopharma LLP, based in Hyderabad, supply Velpatasvir APIs to both domestic and international markets.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to leading companies such as Alembic Pharmaceuticals, Zydus Lifesciences, and Torrent Pharmaceuticals, which are involved in the development and manufacturing of finished dosage forms. These companies have a strong presence in both domestic and international markets, contributing to the export of formulations containing Velpatasvir.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceuticals. This region houses major pharmaceutical companies like Sun Pharmaceutical Industries Limited, which manufacture and export a wide range of pharmaceutical products, including those containing Velpatasvir. The strategic location and well-established infrastructure facilitate efficient distribution to international markets.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a significant pharmaceutical manufacturing hub, primarily due to favorable tax incentives. This area attracts numerous pharmaceutical companies focusing on the production of generic drugs and formulations. The cost advantages and supportive policies make it an attractive location for manufacturing pharmaceuticals, including Velpatasvir-based products.
5Sourcing Recommendations
- Diversify Supplier Base: While major suppliers like Mylan Laboratories Limited and Hetero Labs Limited dominate the Velpatasvir market, consider engaging with other manufacturers in different clusters to mitigate supply chain risks.
- Evaluate Cluster Specializations: Align sourcing strategies with the strengths of each pharmaceutical cluster. For instance, source APIs from Hyderabad and formulations from the Ahmedabad-Vadodara region to leverage regional expertise.
- Assess Export Capabilities: Prioritize suppliers in the Mumbai-Thane-Raigad region for export-oriented products, given their established infrastructure and proximity to international shipping routes.
- Leverage Incentive Zones: Explore partnerships with manufacturers in tax incentive zones like Baddi-Nalagarh to benefit from cost advantages and favorable regulatory environments.
By strategically engaging with India's diverse pharmaceutical clusters, companies can optimize their supply chains for Velpatasvir and enhance their competitive positioning in the global market.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Velpatasvir exporters from India
Natco Pharma Limited — Natco Pharma acquires 35.75% stake in Adcock Ingram
In November 2025, Natco Pharma completed the acquisition of a 35.75% stake in Adcock Ingram, a South African pharmaceutical company, for approximately US$226 million. This acquisition led to the delisting of Adcock Ingram from the Johannesburg Stock Exchange. - IMPACT: This strategic move is expected to enhance Natco Pharma's global footprint, potentially increasing Velpatasvir exports to the African market.
Impact: This strategic move is expected to enhance Natco Pharma's global footprint, potentially increasing Velpatasvir exports to the African market.
Hetero Labs Limited — Hetero Labs receives FDA approval for new Velpatasvir formulation
In December 2024, Hetero Labs Limited received approval from the U.S. Food and Drug Administration (FDA) for a new formulation of Velpatasvir, enhancing its therapeutic efficacy. - IMPACT: This approval is anticipated to boost Hetero Labs' Velpatasvir production and export capabilities, particularly to the U.S. market.
Impact: This approval is anticipated to boost Hetero Labs' Velpatasvir production and export capabilities, particularly to the U.S. market.
Mylan Laboratories Limited — Mylan partners with Gilead Sciences for Velpatasvir distribution
In March 2025, Mylan Laboratories Limited entered into a collaboration agreement with Gilead Sciences to distribute Velpatasvir in emerging markets, aiming to increase accessibility to hepatitis C treatments. - IMPACT: This partnership is likely to expand Mylan's Velpatasvir export volumes, especially in developing regions.
Impact: This partnership is likely to expand Mylan's Velpatasvir export volumes, especially in developing regions.
Common Questions — Velpatasvir Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which velpatasvir supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, MYLAN LABORATORIES LIMITED leads with 63 recorded shipments worth $12.2M. HETERO LABS LIMITED (74 shipments) and EURO LIFECARE PRIVATE LIMITED (7 shipments) are also established high-volume exporters.
Q How many velpatasvir manufacturers are there in India?
India has 103 active velpatasvir exporters with a combined export market of $24.7M across 671 shipments to 95 countries. The top 5 suppliers hold 92.8% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for velpatasvir from India?
Average FOB unit price: $88.44 per unit, ranging from $0.94 to $6479.33. Average shipment value: $36.7K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 103 verified Indian exporters of Velpatasvir ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 671 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 95 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
671 Verified Shipments
103 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists